Considering the reasons behind the jump in licensing deal values, Chan added: “Licensing agreement deal values for mRNA-based ...

The mRNA Revolution When the COVID-19 pandemic struck, the world's medical community initially prepared for a disaster of the scale of the Spanish Flu, which struck during WW1 and killed 50 million ...

Discover why the stock prices of mRNA therapy creators BioNTech and Moderna have plummeted and whether they are still worth ...

The FDA has implemented a partial hold on a phase 3 non-small cell lung cancer trial run by BioNTech and OncoC4 after seeing ...

The U.S. Food and Drug Administration has asked a federal judge in Texas to throw out a public records lawsuit related to ...

BioNTech (NASDAQ:BNTX) shares fell Friday after the company said it had been informed by partner OncoC4 that FDA placed ...

BioNTech (BNTX) and OncoC4 have had a partial clinical hold placed by the FDA on a Phase 3 study for BNT316/ONC-392 in the ...

Factors associated with increased flare rates post-vaccination included active disease at the time, female sex, and -- most ...

The FDA approved the company's COVID vaccine in October 2023. The stock has gained 111% in the year to date, while the S&P 500 SPX has gained 22%. This content was created by MarketWatch, which is ...

The lawsuit focuses on scientific work that helped clear the path for creating mRNA vaccines to fight the COVID-19 pandemic.

The clinical hold affects Novavax’s COVID-flu combo and standalone flu vaccines, which were on the cusp of Phase III testing.

The lawsuits claim that Moderna used and profited from crucial mRNA technology in its COVID-19 vaccine Spikevax and ...